Quotes 5-day view Real-time Euronext Bruxelles
01/12/2021
01/13/2021
01/14/2021
01/15/2021
01/18/2021
Date
85.84(c)
87.78(c)
88.1(c)
86.84(c)
85.78 Last
194 789
312 850
267 100
294 911
100 107 Volume
-0.88% +2.26% +0.36% -1.43% -1.22% Change
Sales 2020
5 201 M 6 272 M 6 272 M
Net income 2020
755 M 911 M 911 M
Net Debt 2020
1 376 M 1 659 M 1 659 M
P/E ratio 2020
22,3x
Yield 2020
1,46%
Sales 2021
5 463 M 6 588 M 6 588 M
Net income 2021
908 M 1 095 M 1 095 M
Net Debt 2021
630 M 760 M 760 M
P/E ratio 2021
18,3x
Yield 2021
1,55%
Capitalization
16 408 M 19 838 M 19 785 M
EV / Sales 2020
3,42x
EV / Sales 2021
3,12x
Nbr of Employees
7 600
Free-Float
62,2%
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Notations Surperformance© of UCB
Trading Rating : Investor Rating :
News in other languages on UCB
Analyst Recommendations on UCB
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends UCB
Short Term Mid-Term Long Term Trends Neutral Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
18
Average target price
109,59 €
Last Close Price
86,84 €
Spread / Highest target
55,5%
Spread / Average Target
26,2%
Spread / Lowest Target
-4,42%
Please enable JavaScript in your browser's settings to use dynamic charts.
1st jan. Capitalization (M$)
UCB 2.79% 19 838
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
